Biomea's diabetes drug shows promise, may work for those responding to GLP-1 – Reuters
- Biomea’s diabetes drug shows promise, may work for those responding to GLP-1 Reuters
- Icovamenib shows sustained benefits for hard-to-treat diabetes patients Investing.com
- Biomea Fusion Announces Positive Phase II Study Results TipRanks
- Biomea Fusion Reports Positive 52-Week Results from Phase II COVALENT-111 Study of Icovamenib in Type 2 Diabetes Patients Quiver Quantitative
- Biomea Fusion reports 52-week results from Phase II diabetes trial Investing.com